Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

BackgroundOlodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-h duration of action investigated in asthma and chronic obstructive pulmonary disease.MethodsTwo multicentre studies examined the efficacy and safety of 4 weeks’ once-daily (QD) olodaterol (2, 5, 10 and 20 μg, with background inhaled corticosteroids) in patients with asthma. One randomised, double-blind, parallel-group study (1222.6; 296 patients) administered …